

NOW AVAILABLE

CYTOPOINT™

the first monoclonal antibody licensed for the  
treatment of canine atopic dermatitis<sup>1</sup>



FROM ITCHY AND ANGRY



TO IZZY AND ANGIE

4-8  
WEEKS OF  
RELIEF\*

CYTOPOINT™ offers 4 to 8 weeks of relief with a single in-office injection, helping to improve the quality of life for dogs with atopic dermatitis and their families<sup>2</sup>



### TARGETED

Targets and neutralizes interleukin (IL)-31, a key itch-inducing cytokine in atopic dermatitis<sup>3</sup>



### WORKS FAST AND LASTS

Begins working within 1 day and delivers 4 to 8 weeks of relief\* from the clinical signs of atopic dermatitis; in-office administration ensures compliance<sup>2</sup>



### SAFE

Safe for dogs of all ages, even those with concomitant diseases, and can be used with many common medications<sup>4,5</sup>

**CYTOPOINT puts long-lasting control of  
canine atopic dermatitis in your hands**

To learn more, contact your Zoetis representative or visit [www.CYTOPOINT.com](http://www.CYTOPOINT.com)

\*Repeat administration every 4 to 8 weeks as needed in the individual patient.<sup>1</sup>

**Indication:** CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

**References:** 1. Data on file, Press Release, August 2015, Zoetis LLC. 2. Data on file, Study Report No. C863R-US-12-018, Zoetis LLC.

3. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. *Vet Dermatol.* 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x. 4. Data on file, Study Report No. C362N-US-13-042, Zoetis LLC.

5. Data on file, Study Report No. C961R-US-13-051, Zoetis LLC.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2016 Zoetis Services LLC. All rights reserved. CYT-00100

zoetis

CYTOPOINT™